Bart Filius Biography and Net Worth

Director of ProQR Therapeutics

Bart Filius has served on our board since 2019. He is the former President and Chief Operating Officer of Galapagos, a position he held from 2021 to 2023. He joined Galapagos in 2014 as Chief Financial Officer and added the role of Chief Operating Officer in 2017. Prior to joining Galapagos, Mr. Filius held a variety of executive positions at Sanofi, where he was Vice President, Chief Financial Officer Europe, Country manager for The Netherlands and Vice President for Mergers & Acquisitions. Prior to joining Sanofi, Mr. Filius was a strategy consultant at Arthur D. Little. Mr. Filius currently holds a board position at Idorsia Ltd.. Mr. Filius has an MBA degree from INSEAD and a bachelor’s degree in Business from Nyenrode University.

What is Bart Filius' net worth?: The estimated net worth of Bart Filius is at least $621 thousand as of July 17th, 2026. Mr. Filius owns 300,000 shares of ProQR Therapeutics stock worth more than $621,000 as of September 5th. This net worth evaluation does not reflect any other assets that Mr. Filius may own. Learn More about Bart Filius' net worth.
How do I contact Bart Filius?: The corporate mailing address for Mr. Filius and other ProQR Therapeutics executives is Zernikedreef 9, Leiden P7, 2333 CK. ProQR Therapeutics can also be reached via phone at (188) 166-7000 and via email at [email protected]. Learn More on Bart Filius' contact information.
Has Bart Filius been buying or selling shares of ProQR Therapeutics?: During the last ninety days, Bart Filius has bought $258,000.00 of ProQR Therapeutics stock. Most recently, on Friday, July 17th, Bart Filius bought 150,000 shares of ProQR Therapeutics stock. The stock was acquired at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the transaction, the director now directly owns 300,000 shares of the company's stock, valued at $516,000. Learn More on Bart Filius' trading history.
Who are ProQR Therapeutics' active insiders?: ProQR Therapeutics' insider roster includes Daniel de Boer (Founding CEO), and Bart Filius (Director). Learn More on ProQR Therapeutics' active insiders.
Are insiders buying or selling shares of ProQR Therapeutics?: During the last year, ProQR Therapeutics insiders bought shares 4 times. They purchased a total of 600,000 shares worth more than $988,500.00. The most recent insider tranaction occured on July, 17th when Director Bart Filius bought 150,000 shares worth more than $258,000.00. Insiders at ProQR Therapeutics own 8.4% of the company. Learn More about insider trades at ProQR Therapeutics.
Information on this page was last updated on 7/17/2026.

Bart Filius Insider Trading History at ProQR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/17/2026	Buy	150,000	$1.72	$258,000.00	300,000
6/26/2026	Buy	150,000	$1.54	$231,000.00	150,000

Bart Filius Buying and Selling Activity at ProQR Therapeutics

ProQR Therapeutics Company Overview

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Today's Range

Now: $2.07

$2.06

$2.11

50 Day Range

MA: $1.91

$1.66

$2.43

2 Week Range

Now: $2.07

$1.33

$3.10

Volume

368,448 shs

Average Volume

900,722 shs

Market Capitalization

$218.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.06